ABCL — AbCellera Biologics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703057 ·
Last close
$11.03
Market Cap
$3.60B
52W High
$15.02
52W Low
$2.74
ADV30
3,645,785
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 10,639,000 | — | -49,679,000 | -40,758,000 | 1,499,864,000 | 163,800,000 | 437,364,000 |
| Jun 2026 | 4,050,000 | — | -58,923,000 | -55,427,000 | 1,307,575,000 | 120,065,000 | 411,555,000 |
| Mar 2026 | 8,315,000 | — | -53,180,000 | -43,165,000 | 1,307,112,000 | 77,063,000 | 369,029,000 |
| Dec 2025 | 44,853,000 | — | -25,266,000 | -8,945,000 | 1,356,950,000 | 128,513,000 | 390,046,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,430,000
Investing CF
$-122,038,000
Financing CF
$218,337,000
CapEx
$-17,420,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.64
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-168,832,000
Inventory
$7,569,000
Receivables
$67,276,000
ST Investments
$600,624,000
EBIT TTM
$-187,048,000
Pretax Income TTM
$-170,813,000
Interest Exp TTM
$42,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,170,000
EBITDA
$-199,960,000
Free Cash Flow
$-46,431,124
Enterprise Value
$3,428,156,416
Total Cash
$540,104,000
Total Debt
$135,616,992
Shares Out
326,617,896
Trailing EPS
$-0.48
Book Value
$3.22
ROE
-17.3%
ROA
-10.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 75,128,000 | -203,213,000 | -146,412,000 | 1,356,950,000 | 390,046,000 | 966,904,000 | -131,295,000 |
| Dec 2024 | 28,833,000 | -301,146,000 | -162,857,000 | 1,360,553,000 | 304,469,000 | 1,056,084,000 | -108,556,000 |
| Dec 2023 | 38,025,000 | -223,052,000 | -146,398,000 | 1,488,094,000 | 335,776,000 | 1,152,318,000 | -43,877,000 |
| Dec 2022 | 485,424,000 | 227,065,000 | 158,519,000 | 1,540,907,000 | 307,630,000 | 1,233,277,000 | 277,360,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$66,174,000
NetIncome TTM
$-164,656,000
OpCashFlow TTM
—
Assets (Latest)
$1,307,575,000
Forward EPS
$-0.70
Max Pain — expiry 2027-01-15
max pain strike: $7.00 · spot: $11.02 · call oi: 45,073 · put oi: 29,568
Expected Move to 2027-01-15:
±$2.70
(24.50%) —
implied range
$8.32 –
$13.72
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OGN | Organon & Co. | $3.65B | $13.90 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.54B | $27.52 | — |
| PBLS | Parabilis Medicines, Inc. | $3.49B | $28.25 | — |
| IRON | Disc Medicine, Inc. | $3.49B | $76.57 | — |
| TNGX | Tango Therapeutics, Inc. | $3.75B | $22.11 | — |
News headlines (Yahoo Finance, 1h cache)
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
2026-11-16 22:12 · Yahoo
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
2026-11-12 13:40 · Yahoo
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
2026-11-12 13:14 · Yahoo
AbCellera Biologics Inc (ABCL) (Q3 2026) Earnings Call Highlights: Breakthrough Hot Flash Data ...
2026-11-10 15:04 · Yahoo
AbCellera (ABCL) Q3 2026 Earnings Call Transcript
2026-11-10 07:02 · Yahoo
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
2026-11-10 02:14 · Yahoo
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
2026-11-09 21:35 · Yahoo
AbCellera Reports Q3 2026 Business Results
2026-11-09 21:05 · Yahoo
AbCellera (ABCL) Stock May Look Fully Priced On Book Value
2026-11-06 03:21 · Yahoo
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
2026-11-05 21:05 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-13 12:41:20 | 2026-11-13 | Booth Andrew | CFO | P - Purchase | 11.33 | 8600 | 97438 |